Q-omics provides the consensus-scored GOLGA4 profile across patient tissues and cancer cell-line models. GOLGA4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GOLGA4 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, GOLGA4 RNA expression shows 21,372 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where GOLGA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA4 survival associations across molecular data types. GOLGA4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA4 RNA expression–survival associations across cancer types. High GOLGA4 expression shows unfavorable associations in LGG, LUSC and THCA, but favorable associations in KIRC, SKCM and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GOLGA4 RNA expression.
This table summarizes GOLGA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GOLGA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA4 shows lower tumor expression in THCA, HNSC, KIRC, COAD and LUSC and higher tumor expression in LIHC. The THCA box plot shows higher GOLGA4 RNA expression in normal versus tumor tissue (log2 FC = −0.856, t-test p < 0.001).
This table shows molecular features associated with GOLGA4 in patient tissues and cancer cell lines. In patient samples, GOLGA4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLGA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
